Enterprise Value
843.7M
Cash
322.2M
Avg Qtr Burn
-41.73M
Short % of Float
28.50%
Insider Ownership
8.99%
Institutional Own.
90.81%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) Details Intestinal infection, Gastroesophageal reflux disease, Esophagitis | Approved Quarterly sales | |
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease | Approved Quarterly sales | |
VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker) Details Bacterial infection | Approved Quarterly sales | |
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease | Phase 3 Initiation | |
VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker) Details Eosinophilic Esophagitis | Phase 2 Initiation |